
    
      Î³-globin reactivated autologous hematopoietic stem cells will be manufactured using
      Crispr/Cas9 gene editing system. Subject participation for this study will be 1 year.
      Subjects who enroll in this study will be asked to participate in a subsequent long-term
      follow up study that will monitor the safety and efficacy of the treatment they receive for
      up to 15 years post-transplant.
    
  